| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 25mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
S-Dihydrodaidzein is a phytoestrogen that targets estrogen receptors. It acts as a weak estrogen agonist or antagonist, modulating estrogenic signaling pathways. This activity is responsible for many of its potential health effects, including benefits for bone health, cardiovascular health, and the reduction of menopausal symptoms. Its effects are mediated through binding to estrogen receptor α and β.
|
|---|---|
| ln Vitro |
In vitro, S-Dihydrodaidzein displays a range of biological activities typical of phytoestrogens. It has been shown to affect cell proliferation in estrogen-responsive cancer cell lines, such as MCF-7 breast cancer cells. It also exhibits antioxidant properties, protecting cells from oxidative damage. Its ability to modulate estrogen receptor activity makes it a subject of research in hormone-related conditions.
|
| ln Vivo |
In vivo, the effects of S-Dihydrodaidzein are related to its role as a soy isoflavone metabolite. It is believed to contribute to the health benefits associated with soy consumption, including reduced risk of osteoporosis, cardiovascular disease, and certain cancers. Its estrogenic and antioxidant activities are thought to be key mechanisms for these benefits.
|
| Enzyme Assay |
The in vitro receptor binding assay for S-Dihydrodaidzein involves competitive binding studies. The compound is incubated with estrogen receptor α or β and a radiolabeled ligand, such as [3H]-estradiol. The amount of radioligand displaced is measured to determine the relative binding affinity (IC50) of S-Dihydrodaidzein for the receptor.
|
| Cell Assay |
In vitro cell culture studies utilize estrogen-responsive cell lines like MCF-7 breast cancer cells. Cells are treated with S-Dihydrodaidzein, and cell proliferation is measured using a colorimetric assay like MTT. The expression of estrogen-responsive genes (e.g., pS2, TGF-β) is analyzed by qPCR or Western blotting to assess its agonist or antagonist activity.
|
| Animal Protocol |
In vivo animal models for studying S-Dihydrodaidzein's effects include ovariectomized rat models of menopause. In these models, rats are treated with the compound, and endpoints such as bone mineral density (via DXA), uterine weight, and serum lipid profiles are assessed to evaluate its estrogenic and bone-protective effects.
|
| ADME/Pharmacokinetics |
S-Dihydrodaidzein is a metabolite with a molecular weight of 256.25 g/mol. It is soluble in DMSO and other organic solvents. As a metabolite, its pharmacokinetics are related to the consumption of its parent compound, daidzein. It is absorbed from the gut and circulated in the bloodstream, where it can be further metabolized or conjugated. It is stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for S-Dihydrodaidzein are limited. As a phytoestrogen, it is generally considered safe at levels obtained through dietary soy consumption. However, high doses or prolonged exposure could potentially have hormonal effects. It is a research compound and is not intended for therapeutic use, so comprehensive toxicity studies are not available.
|
| References |
|
| Additional Infomation |
It has been reported that licorice (Glycyrrhiza uralensis) and pericopsis mooniana contain s-dihydrogenase, and relevant data are available for reference.
S-Dihydrodaidzein is a research compound and an analytical standard used to study isoflavone metabolism. It is not an approved drug. It is a key metabolite in the gut-microbiome axis, and its levels in biological fluids can be used as a biomarker for soy consumption and for studying the inter-individual variability in isoflavone metabolism, which can affect the health benefits of soy. |
| Molecular Formula |
C15H12O4
|
|---|---|
| Molecular Weight |
256.2534
|
| Exact Mass |
256.073
|
| CAS # |
879559-75-8
|
| PubChem CID |
11492597
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
529.5±50.0 °C at 760 mmHg
|
| Flash Point |
206.9±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.662
|
| LogP |
2.79
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1[C@@H](C(=O)C2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O
|
| InChi Key |
JHYXBPPMXZIHKG-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,16-17H,8H2/t13-/m1/s1
|
| Chemical Name |
(3S)-7-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9024 mL | 19.5122 mL | 39.0244 mL | |
| 5 mM | 0.7805 mL | 3.9024 mL | 7.8049 mL | |
| 10 mM | 0.3902 mL | 1.9512 mL | 3.9024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
